flupirtine has been researched along with Nervous System Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Busquet, N; Diaz, MJ; Gonzalez, MI; Lam, PM; Laoprasert, M; Raol, YH; Sampath, D; White, AM | 1 |
| Althaus, M; Hanschmann, A; Klein, T; Magerl, W; Treede, RD | 1 |
| Lawson, K | 1 |
1 review(s) available for flupirtine and Nervous System Diseases
| Article | Year |
|---|---|
Is there a role for potassium channel openers in neuronal ion channel disorders?
Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Epilepsy; Humans; Ion Channels; Isaacs Syndrome; Membrane Potentials; Mice; Mice, Neurologic Mutants; Mutation; Nervous System Diseases; Neuroprotective Agents; Parkinson Disease; Phenylenediamines; Potassium Channels | 2000 |
1 trial(s) available for flupirtine and Nervous System Diseases
| Article | Year |
|---|---|
Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia.
Topics: Aminopyridines; Analgesics; Capsaicin; Cross-Over Studies; Cyclopentanes; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hyperalgesia; Injections, Intradermal; Nervous System Diseases; Pain; Physical Stimulation; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2008 |
1 other study(ies) available for flupirtine and Nervous System Diseases
| Article | Year |
|---|---|
Effects of a potassium channel opener on brain injury and neurologic outcomes in an animal model of neonatal hypoxic-ischemic injury.
Topics: Aminopyridines; Animals; Animals, Newborn; Anticonvulsants; Brain; Brain Injuries; Carotid Arteries; Cognition; Disease Models, Animal; Hand Strength; Hypoxia; Hypoxia-Ischemia, Brain; Male; Maze Learning; Motor Skills; Nervous System Diseases; Neuroprotection; Neuroprotective Agents; Potassium Channels; Quality of Life; Rats; Seizures | 2020 |